Delivra Exposes that the Cannabis Market Requires Further Standardization and Rigourous Testing

TSXV: DVA

TORONTO, May 3, 2018 /CNW/ - Delivra Corp. ("Delivra", or "the Company") today announced the publication of their analytical evaluation of a variety of third-party over-the-counter hemp consumer products for tetrahydrocannabinol ("THC") and cannabidiol ("CBD") content to further develop its internal expertise and evaluate the consumer landscape.

The publication conducted out of Delivra's research lab in Charlottetown, PEI and partially funded by Skills-PEI and by the Atlantic Canada Opportunities Agency, concluded that most third-party consumer products met the federal guidelines on THC content. However, the levels of CBD were higher than THC in multiple products and reflects the lack of federally mandated CBD testing of hemp-based finished products. As a tool, the testing method is amenable to a variety of consumer products indicating its general applicability towards cannabis oils and more complex materials like creams and edibles. Delivra is well positioned to be a preferred Company of choice to provide the standardization of testing for the cannabis industry. These results have now been published in the respected peer-reviewed scientific journal, PLOS ONE, under the title, "A reliable and validated LC-MS/MS method for the simultaneous quantification of 4 cannabinoids in 40 consumer products". The article may be found at the following link: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0196396.

"This data underscores the variety of analytical expertise Delivra has developed in response to the intended legalization of cannabis-based products in Canada and is aligned with several active agreements between Delivra and third-party companies requesting our analytical and formulary expertise. Combining Delivra's unique knowledge of delivery systems with core analytical expertise prepares our Company for further future opportunities in cannabis product development with a focus on safety and consistency," said Dr. Joseph Gabriele, CEO of Delivra.

ABOUT DELIVRA CORP.

Delivra Corp. is a specialty biotechnology company having a proprietary transdermal delivery system platform that can shuttle pharmaceutical and natural molecules through the skin, in a targeted manner. Delivra manufactures and sells a growing line of natural topical creams with the proprietary transdermal delivery system platform under the LivRelief^TM brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and under the LivSport^TM brand for sports performance. LivRelief^TM products are available in pharmacies, grocery chains, and independent health food stores across Canada, including, but not limited to, Shoppers Drug Mart, Walmart, Loblaw, Rexall, Pharmasave, London Drugs, and on-line at www.livrelief.com. In parallel with its consumer products business, Delivra also has a mandate to license its patent-pending, proprietary transdermal delivery technology platform to pharmaceutical companies globally, for the repurposing of pharmaceutical molecules transdermally to treat a broad range of conditions, along with licensing its over-the-counter products globally. Delivra is headquartered in Hamilton, Ontario and has a research and development laboratory in Charlottetown, PEI.

Further information on Delivra can be found at www.delivracorp.comhttp://www.delivracorp.com/ and www.livrelief.com.

Cautionary Note Regarding Forward-Looking Statements

This news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute "forward-looking statements", which are not comprised of historical facts. Forward-looking statements may be identified by such terms as "believes", "anticipates", "intends", "expects", "estimates", "may", "could", "would", "will", or "plan", and similar expressions. Specifically, forward-looking statements in this news release include, without limitation, statements regarding: the Company's revenues and financial performance; the Company's drug research and development plans; the timing of operations; and estimates of market conditions. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events, performance, or achievements of Delivra to differ materially from those anticipated or implied in such forward-looking statements. The Company believes that the expectations reflected in these forward-looking statements are reasonable, but there can be no assurance that actual results will meet management's expectations. In formulating the forward-looking statements contained herein, management has assumed that business and economic conditions affecting Delivra will continue substantially in the ordinary course and will be favourable to Delivra; that the Company will continue to complete orders with existing customers and control product pricing and expenses that clinical testing results will justify commercialization of the Company's drug candidates; that Delivra will be able to obtain all requisite regulatory approvals to commercialize its drug candidates, that such approvals will be received on a timely basis, and that Delivra will be able to find suitable partners for development and commercialization of its products and intellectual property on favourable terms. Although these assumptions were considered reasonable by management at the time of preparation, they may prove to be incorrect. Factors that may cause actual results to differ materially from those anticipated by these forward-looking statements include: the ability of the Company to maintain existing product sales with current customers at existing product pricing and expenses; uncertainties associated with obtaining regulatory approval to perform clinical trials and market products; the need to establish additional corporate collaborations, distribution or licensing arrangements; the ability of the Company to generate sales and profits; the Company's ability to raise additional capital if and when necessary; intellectual property disputes; increased competition from pharmaceutical and biotechnology companies; changes in equity markets, inflation, and changes in exchange rates; and other factors as described in detail in Delivra's public filings, all of which may be viewed on SEDAR (www.sedar.com). Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. Except as required by law, Delivra disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Delivra Corp

Dr. Joseph Gabriele, Chief Executive Officer, 905-561-5014 or Investor Relations: Joanna Longo, [email protected], 416-238-1414 x233